SNDX Syndax Pharmaceuticals Inc

  1. Stocks
  2. Healthcare
  3. NASDAQ: SNDX

Price (delayed)

$17.64

Market cap

$1.58B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$2.51

Enterprise value

$1.83B

Sign up for free to view scoring metrics ?
Relative Growth: Rel. Growth:
Relative Strength: Rel. Strength:
Relative Valuation: Rel. Valuation:
Relative Profitability: Rel. Profitability: 34

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include Revuforj ® (revumenib), an FDA-approved menin inhibitor, and Niktimvo™ (axatilimab-csfr), ...

Highlights
The quick ratio has grown by 41% YoY and by 28% from the previous quarter
The EPS is up by 35% year-on-year and by 10% since the previous quarter
SNDX's equity has shrunk by 90% YoY and by 64% QoQ
SNDX's debt has soared by 71% from the previous quarter and by 71% YoY
Sector: Healthcare
Industry: Biotechnology
Website: http://www.syndax.com
Peers: OLMA OMER VIVS ORIC

Key stats

What are the main financial stats of SNDX

SNDX stock price

How has the Syndax Pharmaceuticals stock price performed over time
Intraday
-3%
1 week
2.08%
1 month
-10.23%
1 year
18.79%
YTD
-16.04%
QTD
-19.3%

Financial performance

How have Syndax Pharmaceuticals's revenue and profit performed over time
Revenue
$252.25M
Gross profit
$241.6M
Operating income
-$194.17M
Net income
-$220.77M
Gross margin
95.8%
Net margin
-87.5%
The operating margin has surged by 82% year-on-year and by 25% since the previous quarter
SNDX's net margin has soared by 80% YoY and by 22% from the previous quarter
The operating income has grown by 43% YoY and by 13% from the previous quarter
The net income has grown by 34% YoY and by 9% from the previous quarter

Price vs fundamentals

How does SNDX's price correlate with its fundamentals

Growth

What is Syndax Pharmaceuticals's growth rate over time

Valuation

What is Syndax Pharmaceuticals stock price valuation
P/E
N/A
P/B
103.52
P/S
6.22
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
7.25
The EPS is up by 35% year-on-year and by 10% since the previous quarter
SNDX's price to book (P/B) is 96% higher than its last 4 quarters average of 54.4
SNDX's equity has shrunk by 90% YoY and by 64% QoQ
The stock's P/S is 35% below its last 4 quarters average of 9.9
The revenue has grown by 16% from the previous quarter

Efficiency

How efficient is Syndax Pharmaceuticals business performance
The company's return on equity has shrunk by 186% YoY and by 45% QoQ
The return on sales has surged by 82% year-on-year and by 25% since the previous quarter
The return on invested capital rose by 48% year-on-year and by 18% since the previous quarter
Syndax Pharmaceuticals's return on assets has increased by 30% YoY and by 13% QoQ

Dividends

What is SNDX's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for SNDX.

Financial health

How did Syndax Pharmaceuticals financials performed over time
The total assets is 2.2% more than the total liabilities
The total liabilities has surged by 60% since the previous quarter and by 57% year-on-year
The total assets has grown by 49% from the previous quarter and by 18% YoY
SNDX's equity has shrunk by 90% YoY and by 64% QoQ
SNDX's debt has soared by 71% from the previous quarter and by 71% YoY

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.